Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Eric Morand, MD, PhD

Dean of Sub-Faculty​ Clinical and Molecular Medicine​, Head of Rheumatology
Monash University
Clayton, Victoria, Australia

Eric Morand is a Professor at Monash University and Director of Rheumatology at Monash Health. His group studies glucocorticoid biology, lupus outcomes and clinical endpoint development.

Presentation(s):

  • 0595: Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atomwise: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cullinan: Consultant (Ongoing); Dragonfly: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dren Bio: Consultant (Terminated, November 30, 2024); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); GlaxoSmithKline(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Kymera: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Orna: Consultant (Ongoing); Quell: Consultant (Terminated, December 31, 2024); Remegen: Consultant (Terminated, December 31, 2024); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Zenas: Consultant (Ongoing)

  • 0802: Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study

    Sunday, October 26, 2025
    1:15 PM - 1:30 PM Central Time

    Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atomwise: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cullinan: Consultant (Ongoing); Dragonfly: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dren Bio: Consultant (Terminated, November 30, 2024); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); GlaxoSmithKline(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Kymera: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Orna: Consultant (Ongoing); Quell: Consultant (Terminated, December 31, 2024); Remegen: Consultant (Terminated, December 31, 2024); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Zenas: Consultant (Ongoing)

  • 2445: Achievement of Treat to Target Measures with Upadacitinib in Patients with Systemic Lupus Erythematosus: Phase 2 Randomized Sleek Clinical Trial Results

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atomwise: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cullinan: Consultant (Ongoing); Dragonfly: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dren Bio: Consultant (Terminated, November 30, 2024); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); GlaxoSmithKline(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Kymera: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Orna: Consultant (Ongoing); Quell: Consultant (Terminated, December 31, 2024); Remegen: Consultant (Terminated, December 31, 2024); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Zenas: Consultant (Ongoing)

  • 2696: Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE

    Wednesday, October 29, 2025
    12:15 PM - 12:30 PM Central Time

    Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atomwise: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cullinan: Consultant (Ongoing); Dragonfly: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dren Bio: Consultant (Terminated, November 30, 2024); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); GlaxoSmithKline(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Kymera: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Orna: Consultant (Ongoing); Quell: Consultant (Terminated, December 31, 2024); Remegen: Consultant (Terminated, December 31, 2024); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Zenas: Consultant (Ongoing)